News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EXACT Sciences Corporation (EXAS) Submits First Module of Premarket Approval Application to FDA



12/11/2012 11:12:08 AM

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has submitted to the U.S. Food and Drug Administration the first module of the premarket approval (PMA) application for its stool DNA colorectal cancer screening test. This module was comprised of the required documentation regarding the manufacturing and quality control systems for the product. The modules that remain to be submitted will include analytical and clinical data. “The submission of the first, manufacturing module of our PMA application is an important milestone for the company,” said Kevin T. Conroy, the company’s president and chief executive. “With work on the first module finished, we are focused on completing and submitting the analytical and clinical modules.” The manufacturing module was submitted to the FDA on Friday, Dec. 7. The FDA has up to 45 days to accept the submission.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES